arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Q/C TECHNOLOGIES, INC.

QCLS
$2.90 ▲ +0.09 (+3.38%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
14 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Q/C TECHNOLOGIES, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.0M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -35.8%
FCF / Share $-5.24
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.58M
↓ -5.3%
Net Income Profit after all expenses
$-11.63M
↑ +50.2%
Operating Margin Operating profit as % of sales
-250.2%
↓ -94.6%
FCF / Share Free cash flow per share
$-5.24
↑ +37.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
16
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 54 quarters